logo

For the Inventor, By the Inventor

Cambridge, United Kingdom

Medimmune Limited


USPTO Granted Patents = 546

% Expired Patents = 32.8



Trademarks = 7

Forward Citations = 5,743

Loading Chart...
Loading Chart...

772 inventors (with patents filed for the assignee):

goldMedal Philip Wilson Howard (65 out of 92 patents)

silverMedal George William Kemble (38 out of 41 patents)

bronzeMedal Leslie Sydnor Johnson (33 out of 127 patents)

4.  Herren Wu (32 out of 50 patents)

5.  Changshou Gao (30 out of 32 patents)

6.  Ralph Raymond Minter (30 out of 32 patents)

7.  William Dall'Acqua (22 out of 22 patents)

8.  Patricius Hendrikus Cornelis Van Berkel (21 out of 24 patents)

9.  Hong Jin (21 out of 24 patents)

10.  Melissa Marie Damschroder (21 out of 26 patents)

11.  Scott A Hammond (19 out of 19 patents)

12.  Scott Koenig (19 out of 58 patents)

13.  Chin-Fen Yang (19 out of 19 patents)

14.  Partha S Chowdhury (18 out of 31 patents)

15.  Nicole Kallewaard-LeLay (16 out of 19 patents)


Core Competencies:
Bispecific Binding Proteins
Anti-Influenza Antibodies
Cancer Treatment
Polypeptides
Therapeutic Binding Molecules
Combination Therapies
Antibody-Drug Conjugates
RSV-Specific Antibodies
Amyloid Beta Antibodies
Neurodegenerative Disease Treatments
GDF-15 Antibodies
CD73 Binding Molecules

546 patents:

1. 12715933 - MOLECULES WITH ALTERED NEONATE FC RECEPTOR BINDING HAVING ENHANCED THERAPEUTIC AND DIAGNOSTIC PROPERTIES (2026-08-25),
2. 12686718 - TARGETED BINDING AGENTS AGAINST B7-H1 (2026-07-21),
3. 12630648 - BINDING MOLECULES SPECIFIC FOR CD73 AND USES THEREOF (2026-05-19),
4. 12630600 - GLP-1 AND GLUCAGON DUAL AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY (2026-05-19),
5. 12570744 - BISPECIFIC PD-1 AND TIGIT BINDING PROTEINS AND USES THEREOF (2026-03-10),
6. 12466874 - Prevention of protein disulfide bond reduction (2025-11-11),
7. 12428473 - Combination therapies using anti-pseudomonas PSL and PCRV binding molecules (2025-09-30),
8. 12391768 - Antibodies to ticagrelor and methods of use (2025-08-19),
9. 12371464 - Polypeptides and uses thereof (2025-07-29),
10. 12357692 - Method of treating influenza A (2025-07-15),
11. 12344664 - Antibodies to amyloid beta (2025-07-01),
12. 12325740 - Neutralizing anti-influenza B antibodies and uses thereof (2025-06-10),
13. 12312397 - Anti-O2 antibodies and uses thereof (2025-05-27),
14. 12264194 - Decreasinginfections in colonized patients (2025-04-01),
15. 12224043 - Methods for determining treatment for cancer patients (2025-02-11),
MedImmune Limited is a leading biotechnology company specializing in the research, development, and production of innovative biotherapeutic drugs. With a focus on harnessing the power of the immune system, MedImmune aims to improve the health and wellbeing of individuals worldwide. The company operates with the mission of transforming scientific discoveries into valuable medicines that address unmet medical needs. MedImmune is committed to advancing science and collaborating with partners in academia, government, and industry to drive innovation in the field of biotechnology.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

Medimmune Limited
546 Patents

#2 in Cambridge

#26 in United Kingdom

#1,775 in the World

Cambridge, GB
Cambridge, United Kingdom

Medimmune Limited

Forward Citations = 5,743

772 inventors:

goldMedal Philip Wilson Howard (65 out of 92 patents)

silverMedal George William Kemble (38 out of 41 patents)

bronzeMedal Leslie Sydnor Johnson (33 out of 127 patents)

4.  Herren Wu (32 out of 50 patents)

5.  Changshou Gao (30 out of 32 patents)

Please report any incorrect information to [email protected]
Loading…